Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 4
1984 3
1985 6
1986 4
1987 11
1988 7
1989 9
1990 2
1991 3
1992 3
1993 1
1994 3
1995 5
1996 7
1997 7
1998 5
1999 6
2000 8
2001 5
2002 9
2003 5
2004 8
2005 4
2006 12
2007 17
2008 33
2009 34
2010 23
2011 30
2012 22
2013 30
2014 19
2015 25
2016 25
2017 26
2018 29
2019 18
2020 20
2021 27
2022 20
2023 19
2024 13
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

515 results

Results by year

Filters applied: . Clear all
Page 1
Methylnaltrexone.
[No authors listed] [No authors listed] 2023 Dec 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Dec 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33226751 Free Books & Documents. Review.
No information is available on the use of methylnaltrexone during breastfeeding. The manufacturer recommends avoiding breastfeeding in mothers taking methylnaltrexone. Based on pharmacokinetic data, the oral absorption of methylnaltrexone appears to be very l …
No information is available on the use of methylnaltrexone during breastfeeding. The manufacturer recommends avoiding breastfeeding i …
Methylnaltrexone: Peripherally Acting -Opioid Receptor Antagonist.
Uritsky TJ. Uritsky TJ. J Adv Pract Oncol. 2019 Jan-Feb;10(1):62-67. Epub 2019 Jan 1. J Adv Pract Oncol. 2019. PMID: 31308989 Free PMC article. Review.
There are a number of PAMORAs now available, and methylnaltrexone is the only PAMORA indicated for the treatment of OIC in adults with advanced illness, as well as for patients with chronic noncancer pain, including patients with chronic pain related to prior cancer treatm …
There are a number of PAMORAs now available, and methylnaltrexone is the only PAMORA indicated for the treatment of OIC in adults wit …
Methylnaltrexone: MNTX.
[No authors listed] [No authors listed] Drugs R D. 2006;7(6):374-8. doi: 10.2165/00126839-200607060-00006. Drugs R D. 2006. PMID: 17073520 Review.
Wyeth is also responsible for all future development and commercialisation costs. Wyeth will develop oral methylnaltrexone worldwide. Progenics will lead the US development of subcutaneous and intravenous methylnaltrexone, while Wyeth will lead development of these …
Wyeth is also responsible for all future development and commercialisation costs. Wyeth will develop oral methylnaltrexone worldwide. …
Methylnaltrexone.
Garnock-Jones KP, McKeage K. Garnock-Jones KP, et al. Drugs. 2010 May 7;70(7):919-28. doi: 10.2165/11204520-000000000-00000. Drugs. 2010. PMID: 20426500 Review.
Methylnaltrexone was not associated with any significant changes in pain scores or central opioid withdrawal in these studies. Methylnaltrexone was generally well tolerated in clinical trials; most adverse events were of mild to moderate severity....
Methylnaltrexone was not associated with any significant changes in pain scores or central opioid withdrawal in these studies. Met
Methylnaltrexone bromide for the treatment of opioid-induced constipation.
Mozaffari S, Nikfar S, Abdollahi M. Mozaffari S, et al. Expert Opin Pharmacother. 2018 Jul;19(10):1127-1135. doi: 10.1080/14656566.2018.1491549. Epub 2018 Jul 6. Expert Opin Pharmacother. 2018. PMID: 29979903 Review.
Peripherally acting mu-opioid receptor antagonists (PAMORA) have been developed for the treatment of OIC with methylnaltrexone bromide being the first approved to treat OIC in adults with advanced illness undergoing palliative care. Areas covered: The authors systematicall …
Peripherally acting mu-opioid receptor antagonists (PAMORA) have been developed for the treatment of OIC with methylnaltrexone bromid …
Methylnaltrexone.
Hendrikx JJ, Beijnen JH, Schellens JH. Hendrikx JJ, et al. Oncologist. 2009 Jul;14(7):679-82. doi: 10.1634/theoncologist.2009-0049. Epub 2009 Jul 15. Oncologist. 2009. PMID: 19605844 Free article. Review. No abstract available.
Methylnaltrexone: treatment for opioid-induced constipation.
Licup N, Baumrucker SJ. Licup N, et al. Am J Hosp Palliat Care. 2011 Feb;28(1):59-61. doi: 10.1177/1049909110373507. Epub 2010 Aug 27. Am J Hosp Palliat Care. 2011. PMID: 20801917 Review.
Opioid-induced bowel dysfunction can lead to refractory constipation. Methylnaltrexone bromide is a peripherally acting mu antagonist and is indicated for the treatment of opioid-induced constipation in patients with advanced illness, when response to standard laxative the …
Opioid-induced bowel dysfunction can lead to refractory constipation. Methylnaltrexone bromide is a peripherally acting mu antagonist …
Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration.
Rotshteyn Y, Boyd TA, Yuan CS. Rotshteyn Y, et al. Expert Opin Drug Metab Toxicol. 2011 Feb;7(2):227-35. doi: 10.1517/17425255.2011.549824. Epub 2011 Jan 11. Expert Opin Drug Metab Toxicol. 2011. PMID: 21222554 Review.
At present, the only approved treatment for opioid-induced constipation is methylnaltrexone bromide subcutaneous injection. Methylnaltrexone is a peripherally restricted opioid antagonist with mu-opioid receptor selectivity that can reduce opioid activity in periphe …
At present, the only approved treatment for opioid-induced constipation is methylnaltrexone bromide subcutaneous injection. Methyl
Methylnaltrexone in the Management of Opioid-Associated Urinary Retention in Children.
Suchovsky SB, Reiter PD, Lewis HE, Clevenger AC. Suchovsky SB, et al. J Pediatr Pharmacol Ther. 2022;27(4):373-378. doi: 10.5863/1551-6776-27.4.373. Epub 2022 May 9. J Pediatr Pharmacol Ther. 2022. PMID: 35558358 Free PMC article.
Fourteen patients (56%) had no UOP following methylnaltrexone administration, while 11 (44%) demonstrated a robust increase (median = 0 mL/kg/hr at baseline [IQR 0-0] to 1.96 mL/kg/hr [IQR 1.08-2.22; p = 0.001]) within 6 hours following methylnaltrexone administrati …
Fourteen patients (56%) had no UOP following methylnaltrexone administration, while 11 (44%) demonstrated a robust increase (median = …
Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.
Mehta N, O'Connell K, Giambrone GP, Baqai A, Diwan S. Mehta N, et al. Postgrad Med. 2016;128(3):282-9. doi: 10.1080/00325481.2016.1149017. Epub 2016 Feb 23. Postgrad Med. 2016. PMID: 26839023 Review.
CONCLUSION: Results support the use of methylnaltrexone. Furthermore, the use of methylnaltrexone to induce laxation may decrease use of health care resources, increase work productivity, and improve cost utilization. ...Possible limitations of this study include th …
CONCLUSION: Results support the use of methylnaltrexone. Furthermore, the use of methylnaltrexone to induce laxation may decre …
515 results